WO2016195224A1 - Modèle animal transgénique ayant gène zc4h2 inactivé, et son utilisation - Google Patents

Modèle animal transgénique ayant gène zc4h2 inactivé, et son utilisation Download PDF

Info

Publication number
WO2016195224A1
WO2016195224A1 PCT/KR2016/003348 KR2016003348W WO2016195224A1 WO 2016195224 A1 WO2016195224 A1 WO 2016195224A1 KR 2016003348 W KR2016003348 W KR 2016003348W WO 2016195224 A1 WO2016195224 A1 WO 2016195224A1
Authority
WO
WIPO (PCT)
Prior art keywords
zc4h2
gene
transgenic animal
zebrafish
epilepsy
Prior art date
Application number
PCT/KR2016/003348
Other languages
English (en)
Korean (ko)
Inventor
김철희
유경원
이. 슈와르츠찰스
박두상
Original Assignee
충남대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 충남대학교산학협력단 filed Critical 충남대학교산학협력단
Publication of WO2016195224A1 publication Critical patent/WO2016195224A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Definitions

  • the present invention relates to a transgenic animal model knocking out the ZC4H2 gene and its use.
  • Representative diseases causing movement disorder due to neuronal abnormalities include parkinson's disease and epilepsy.
  • Parkinson's disease is a neurodegenerative disease, and neurodegenerative disease refers to a disease in which nerve cells die due to some cause and cause abnormal brain function. Parkinson's disease, Parkinson's syndrome, etc. are difficult to distinguish the meaning, but the typical symptom is stable tremor, hand tremor, muscle stiffness, postural instability. In Korea, a large-scale study on Parkinson's disease itself is insufficient. The prevalence rate is 374 in 100,000 people over 18 years old and 1.47% in 60 years old.
  • epilepsy is one of chronic neurological disorders, and the rapid development of modern medicine has changed the concept of epilepsy (epilepsy) from past incurable chronic disease to a curable disease.
  • Epilepsy is at the heart of the epileptic seizure (epileptic seizure), epileptic seizure seizures are localized brain lesions, systemic metabolic disorders, drug addiction, hypoxia, head trauma or severe overwork and sleep deprivation It is a central symptom that occurs.
  • Interstitial seizures are defined as neurophysiologically abrupt and disordered cerebral cortical cells, which can be easily understood by clinical seizure EEG findings. It is not yet clear why neuronal cells in normal function abruptly enter into an abnormal state of excitement, but it is understood that the regulation of excitation and suppression for normal brain function is caused by a variety of causes, which are experimental. This is supported by the phenomenon that interstitial seizures occur when the function of excitatory neurotransmitters is increased or the function of inhibitory neurotransmitters is suppressed.
  • the ZC4H2 gene which has been identified as the causative gene of Miles-Carpenter Syndrome (MCS), one of the X-linked intellectual disability (XLID), has been reported to exhibit dyskinesia such as epilepsy during deficits. However, no clear mechanism has been identified.
  • MCS Miles-Carpenter Syndrome
  • XLID X-linked intellectual disability
  • Epilepsy has a high incidence in childhood and old age, and epilepsy patients occur at a rate of about 1% to 1.5% of the world's population. In particular, the incidence rate reported in developing countries and developing countries is more than 100 per 100,000 people. While it is relatively high, it is reported to be relatively low in developed countries such as 40 to 70 people. In particular, it is estimated that there are about 400,000 patients in Korea.
  • Transgenic animals are animals that express their intended genotype by artificially inserting or removing external genes, and can be useful for basic research to identify the role of specific genes in living organisms. . In other words, by inserting or deleting a gene whose function is suspected, and observing how the effect appears, the physiological function mediated by the gene can be inferred.
  • transgenic animals can be used as a model of human disease, and are very useful for identifying the cause of disease, the progress of disease, and the effects or side effects of potential therapeutic drugs.
  • transgenic mice, zebrafish, and the like have been developed for diseases such as dementia, cancer, heart disease, and genetic diseases.
  • a zebrafish is transparent in embryonic embryos, in vitro fertilized, can easily acquire large numbers of fertilized eggs, and develops so rapidly that most tissues and organs are formed in one day.
  • the genetic information of the entire genome has been revealed and can be easily retrieved through the zebrafish database, and because it has the advantage that the composition of the genome is similar to that of humans, it is possible to analyze the function of human genes and target natural products or compounds. It has been usefully used for screening biomodulators. Due to the above advantages, research on transgenic zebrafish has been very active, and the zebrafish transformation technology is easily applied to mammalian technology. Zebrafish embryos are readily available in large numbers, transparent and easy to handle, and have the advantage that various vectors such as retroviral vectors or transposons can be applied.
  • the present inventors are trying to develop a human disease model that can be easily and quickly accessed, and the ZC4H2 gene knockout zebrafish has symptoms of motor disorders very similar to those of Miles-Carpenter Syndrome patients.
  • the expression of neurons and V2b inhibitory neurons was observed to be reduced, and the present invention was completed by confirming that the expression of GABA neurons was restored when ZC4H2 gene was restored to ZC4H2 gene knockout zebrafish.
  • the present invention provides a transgenic animal in which the ZC4H2 gene is knocked out.
  • the present invention provides a transgenic fertilized egg knocked out ZC4H2 gene.
  • the present invention also provides a transgenic sperm in which the ZC4H2 gene is knocked out.
  • step 2) provides a method for screening a disease drug related to a movement disorder comprising comparing the transgenic animal treated with the test compound of step 1) with the untreated control to determine whether symptoms are recovered.
  • step 2) introducing the construct of step 1) into the fertilized egg
  • the present invention provides a transgenic animal in which the ZC4H2 gene is knocked out.
  • the ZC4H2 gene is preferably composed of SEQ ID NO: 9, but is not limited thereto.
  • the transgenic animal is characterized by having a disorder related to movement disorder.
  • the movement-related disorders include epilepsy including posttraumatic epilepsy, Parkinson's disease, pediatric epilepsy, Miles-Carpenter Syndrome, psychosis, migraine, cerebral anemia, Alzheimer's disease, Huntington's chorea, obsessive dementia, obsessive compulsive reaction Abnormalities (OCD), neuropathic defects associated with AIDS, sleep disorders (including insomnia and sleep attacks), convulsions such as Gilles de la Tourette's syndrome, traumatic cerebral damage, tinnitus, neuralgia, neuropathic pain Neurological activity, multiple sclerosis (MS), motor neuron disease, ataxia, myopathy (convulsiveness), temporomandibular joint dysfunction and muscular dystrophy, which cause neurological health defects in diseases such as toothache, cancer pain and diabetes It may be any one selected from the group consisting of (ALS), according to a specific embodiment of the present invention epilepsy, convulsions, seizures, Parkinson's syndrome and children Witness the EEG is characterized.
  • ALS a specific
  • transgenic animal of the manufacturing method is preferably zebrafish, but is not limited thereto, and all animals including monkeys, pigs, horses, cows, sheep, dogs, cats, mice, mice, rabbits, etc. Can be.
  • the inventors found that patients with Miles-Carpenter Syndrome (MCS) disease have a common ZC4H2 mutant gene based on a clinical report, and based on this, polymorphism analysis and expression. Tissue analysis confirmed the variation and expression of the ZC4H2 gene. Subsequently, the gene was isolated from zebrafish, and the homology between amino acid sequences with humans and mice was analyzed (see FIG. 1), and the ZC4H2 gene was mainly expressed near the developing CNS (see FIG. 2). ZC4H2 Gene knockout zebrafish were fabricated (see FIG. 3) and observed.
  • MCS Miles-Carpenter Syndrome
  • ZC4H2 knockout zebrafish showed excessive jaw muscle stiffness compared to normal zebrafish, with abnormally active pectoral fin movement, and human exotropia Similar to the symptoms, the eye was found to be abnormally positioned (see FIG. 4). However, ZC4H2 gene knockout zebrafish confirmed the formation of normal motor neurons and axons as well as normal zebrafish (see FIG. 5). It was observed that the expression of V2a interneurons, GABA neurons, and V2b inhibitory neurons was reduced due to ZC4H2 gene knockout (see FIG. 6). When the ZC4H2 gene was restored to ZC4H2 gene knockout zebrafish, the expression of GABA neurons was decreased. Confirmed recovery (see FIG. 7).
  • ZC4H2 gene knockout zebrafish was treated with retigabine approved as an epilepsy treatment, it was confirmed that abnormally active movement of the jaw and pectoral fin is inhibited (see FIGS. 8 and 9). Therefore, the present invention has prepared a ZC4H2 gene knockout transformed zebrafish showing symptoms similar to epilepsy, convulsions and seizures, and can be usefully used for screening related disease drugs using the same.
  • the present invention provides a transgenic fertilized egg knocked out ZC4H2 gene.
  • the present invention provides a transgenic sperm in which the ZC4H2 gene is knocked out.
  • the ZC4H2 gene is preferably composed of SEQ ID NO: 9, but is not limited thereto.
  • step 2) provides a method for screening a disease drug related to a movement disorder comprising comparing the transgenic animal treated with the test compound of step 1) with the untreated control to determine whether symptoms are recovered.
  • the transgenic animal of step 1) is preferably zebrafish, but is not limited thereto, and may include all animals including monkeys, pigs, horses, cattle, sheep, dogs, cats, mice, mice, rabbits, and the like. have.
  • the transgenic animal is characterized by having a disorder related to movement disorder.
  • the movement-related disorders include epilepsy including posttraumatic epilepsy, Parkinson's disease, pediatric epilepsy, Miles-Carpenter Syndrome, psychosis, migraine, cerebral anemia, Alzheimer's disease, Huntington's chorea, obsessive dementia, obsessive compulsive reaction Abnormalities (OCD), neuropathic defects associated with AIDS, sleep disorders (including insomnia and sleep attacks), convulsions such as Gilles de la Tourette's syndrome, traumatic cerebral damage, tinnitus, neuralgia, neuropathic pain Neurological activity, multiple sclerosis (MS), motor neuron disease, ataxia, myopathy (convulsiveness), temporomandibular joint dysfunction and muscular dystrophy, which cause neurological health defects in diseases such as toothache, cancer pain and diabetes It may be any one selected from the group consisting of (ALS), according to a specific embodiment of the present invention epilepsy, convulsions, seizures, Parkinson's syndrome and children Witness the EEG is characterized.
  • ALS a specific
  • test compound may be selected from the group consisting of natural compounds, synthetic compounds, RNA, DNA, polypeptides, enzymes, proteins, ligands, antibodies, antigens, metabolites of bacteria or fungi, and bioactive molecules. It is not limited.
  • the method of determining whether symptoms are recovered by comparing the transgenic animal treated with the test compound of step 2) with the untreated control for example, PCR method based on tail genomic DNA or abnormal symptoms of knockout embryos
  • PCR method based on tail genomic DNA or abnormal symptoms of knockout embryos The method of discriminating with the naked eye is mentioned, and it is easy to distinguish abnormal symptoms visually.
  • the ZC4H2 gene knockout zebrafish produced by the method of the present invention has movement disorder symptoms similar to those in human patients, and the knockout zebrafish is treated with epilepsy treatment retigabine 5 It was confirmed that seizure symptoms were suppressed in the group treated with the concentration of ⁇ M (see FIGS. 8 and 9). Therefore, the knockout zebrafish of the present invention can be usefully used for drug screening of dyskinesia-related diseases such as epilepsy and Parkinson's disease.
  • step 2) introducing the construct of step 1) into the fertilized egg
  • ZC4H2 gene of step 1) is preferably composed of SEQ ID NO: 9, but is not limited thereto.
  • the knockout construct of step 1) preferably comprises a gene shear, the gene shear is ZFN (zinc-finger nuclease), TALEN (transcription activator-like effector nuclease) and CRISPR / Cas9 (clustered regulary interspaced short palindromic repeats / CRISPR-associated protein-9), but preferably any one selected from the group consisting of, according to the embodiment of the present invention was used to select TALEN.
  • the mutagenic transporter including the TALEN preferably knocks out ZC4H2, but includes all cases in which only a part of the sequence is knocked out as well as the entire ZC4H2 sequence.
  • the fertilized egg of step 2) is preferably a zebrafish (zebrafish) fertilized egg, but is not limited to this, all animals including monkeys, pigs, horses, cattle, sheep, dogs, cats, mice, mice, rabbits, etc. Any derived fertilized egg can be used.
  • zebrafish zebrafish
  • the method of introducing the construct of step 2) into the fertilized egg is a method of using the microinjection (microinjection), electroporation (electroporation), particle bombardment (sperm bombardment), sperm after preparing the gene construct (sperm-mediated gene transfer), viral infection (viral infection), direct muscle injection (direct muscle injection), insulators (insulator) and transposons (transnas) can be selected and appropriately selected.
  • the expression vector was transformed into the zebrafish embryo by microinjection.
  • the step of selecting the ZC4H2 gene knockout embryo of step 3) may be selected according to various methods well known in the art. Examples of such a screening method include a PCR method using a tail genomic DNA as a template or a method of visually discriminating abnormal symptoms of knockout embryos, and it is preferable to visually identify abnormal symptoms.
  • transgenic animal of the manufacturing method is preferably zebrafish, but is not limited thereto, and all animals including monkeys, pigs, horses, cows, sheep, dogs, cats, mice, mice, rabbits, etc. Can be.
  • the transgenic animal is characterized by having a disorder related to movement disorder.
  • the movement-related disorders include epilepsy including posttraumatic epilepsy, Parkinson's disease, pediatric epilepsy, Miles-Carpenter Syndrome, psychosis, migraine, cerebral anemia, Alzheimer's disease, Huntington's chorea, obsessive dementia, obsessive compulsive reaction Abnormalities (OCD), neuropathic defects associated with AIDS, sleep disorders (including insomnia and sleep attacks), convulsions such as Gilles de la Tourette's syndrome, traumatic cerebral damage, tinnitus, neuralgia, neuropathic pain Neurological activity, multiple sclerosis (MS), motor neuron disease, ataxia, myopathy (convulsiveness), temporomandibular joint dysfunction and muscular dystrophy, which cause neurological health defects in diseases such as toothache, cancer pain and diabetes It may be any one selected from the group consisting of (ALS), according to a specific embodiment of the present invention epilepsy, convulsions, seizures, Parkinson's syndrome and children Witness the EEG is characterized.
  • ALS a specific
  • the method may further include the step of preparing a homozygous transformant by crossing the wild type transgenic animal prepared by the method of the present invention.
  • the inventors found that patients with Miles-Carpenter Syndrome (MCS) disease have a common ZC4H2 mutant gene based on a clinical report, and based on this, in zebrafish in which the ZC4H2 gene was knocked out Similar to the symptoms of epilepsy in patients, abnormal stiffness and unstoppable movements of the jaw and pectoral muscles (hyperactivity) and abnormal eye positions (see strabismus) (see Fig. 4), ZC4H2 gene knockout transgenic zebrafish with very similar epilepsy, convulsion and seizure symptoms were constructed.
  • MCS Miles-Carpenter Syndrome
  • the ZC4H2 gene knockout zebrafish was produced, and the ZC4H2 gene knockout zebrafish had dyskinesia, and the expression of V2a interneurons, GABA neurons, and V2b inhibitory neurons was reduced.
  • the ZC4H2 gene knockout zebrafish was restored to the ZC4H2 gene, the expression of GABA neurons was restored, and thus, the ZC4H2 gene knockout zebrafish of the present invention can be usefully used for drug screening methods related to motor disorders. have.
  • Figure 1 shows a comparison of the ZC4H2 amino acid sequence of human, mouse and zebrafish.
  • Figure 2 is a diagram showing the temporal and spatial expression of ZC4H2 in zebrafish.
  • 2A and 2B show temporal and spatial expression patterns of ZC4H2 in 48 hpf zebrafish.
  • FIG. 2C, 2D and 2E are cross-sectional views of FIG. 2B.
  • FIG. 3 is a diagram illustrating a ZC4H2 knockout construct fabrication design using transcription activator-like effector nuclease (TALEN).
  • TALEN transcription activator-like effector nuclease
  • 3A shows the TALEN-mediated mutation target site of ZC4H2 exon2.
  • 3B shows TALEN-mediated mutant lesions.
  • Figure 3C is a diagram showing the PCR results for determining the ZC4H2 gene knockout zebrafish through electrophoresis results.
  • Figure 4 is a diagram showing the hyperactivity of the ZC4H2 gene knock-out zebrafish.
  • 4A and 4B show aspects of the degree and frequency of jaw movement in normal and ZC4H2 gene knockout zebrafish.
  • 4C and 4D show abnormal visual movement of normal and ZC4H2 gene knockout zebrafish.
  • 4E and 4F show abnormal pectoral fin movement of normal and ZC4H2 gene knockout zebrafish.
  • Figure 5 shows the presence of motor neurons of ZC4H2 normal and gene knockout zebrafish.
  • 5A and 5B show the expression of the isl1 gene that labels motor neurons.
  • 5C, 5D, 5E and 5F show the expression of Znp1 protein that labels motor neurons and normal axons.
  • FIG. 6 is a diagram showing the neuronal expression patterns of normal and ZC4H2 gene knockout zebrafish.
  • 6A, 6B, 6C and 6D show expression of vsx2 and vsx1 labeling V2a interneurons and V2a / b precursors.
  • Figures 6E and 6F show the expression of nkx6.1 and dbx2 that label adjacent sites of the ventral neural progenitor domains.
  • 6G and 6H show expression of gad1 labeling GABA neurons.
  • 6I and 6J show the expression of gata3 labeling V2b inhibitory interneurons.
  • 6K and 6L show the expression of glyt2a labeling glycine neurons.
  • 6M and 6N show the expression of vglut2.1 labeling glutamate excitatory neurons.
  • FIG. 7 is a diagram showing the expression of neurons when the ZC4H2 gene is restored to normal and ZC4H2 gene knockout zebrafish.
  • 7A and 7B show gad1 expression of normal zebrafish and ZC4H2 gene knockout zebrafish.
  • 7C, 7D, 7E, and 7F show gad1 expression when ZC4H2 gene is restored to ZC4H2 gene knockout zebrafish.
  • 7G, 7H, 7I, 7J, 7K, and 7L are quantitative analysis results of gad1 expression when ZC4H2 gene knockout was restored in ZC4H2 gene knockout zebrafish and when it was not restored.
  • FIG. 8 is a diagram showing the control effect on abnormal movement of the jaw muscle when the epilepsy treatment retigabine in normal and ZC4H2 gene knockout zebrafish.
  • 8A and 8B are diagrams showing jaw muscle movements when normal zebrafish were treated with and without retigabine.
  • 8C and 8D show jaw muscle movements with and without retigabine in ZC4H2 gene knockout zebrafish.
  • 8E is a diagram showing the results of quantitative analysis of jaw muscle movements when treated with and without retigabine in normal and ZC4H2 gene knockout zebrafish.
  • Figure 9 is a diagram showing the control effect on abnormal pectoral fin movement when retigabine treatment in normal and ZC4H2 gene knockout zebrafish.
  • 9A and 9B are diagrams showing pectoral fin movements with and without retigabine in normal zebrafish.
  • 9C and 9D show pectoral fin movement with and without retigabine in ZC4H2 gene knockout zebrafish.
  • Figure 9E shows the results of quantitative analysis of changes in pectoral fin movement with and without retigabine in normal and ZC4H2 gene knockout zebrafish.
  • MCS Miles-Carpenter Syndrome
  • XLID X-linked intellectual disability
  • Clinical evaluation shows that over 50% of men with MCS disease have intellectual disability, slow speech, small stature, microcephaly, distal muscle weakness, and abnormal feet Rocker-bottom, pes planus, club foot, knee or elbow contractures, narrow shoulders, high torso, ptosis, exotropia, long philtrum ), Highly arched palate, spinal curvature (kyphosis, scoliosis, lordosis), hypotonia, drooling, and Symptoms such as cerebral palsy spasticity.
  • Exon capture and deep sequencing were performed on 718 genes of the X80 chromosome of the K8070 family.
  • an Illumina sequencing library was constructed from gDNA samples of 82 XLID male patients with the Truseq DNA Sample Preparation Kit. Exons of the X chromosome were concentrated using the Agilent SureSelect X chromosome exome kit. Each library was native barcoded and sequenced on the Illumina HiSeq2000 platform using 75-bp or 100-bp pair-end modules. Reorganization and base recalibration of INDEL were performed using GATK. The final mutation results were pretreated by removing the zero range of variation in one strand and the variation close to another variation ( ⁇ 10 bp) in the same sample. Potential XLID mutations were identified using sib-pair comparison filters.
  • the filters were assumed to be rare in unique XLID variations and shared only among affected family members. Variation results in sequencing were found to filter out variations shared between related samples in the population, while those shared between irrelevant samples were removed. In addition, shared mutations in 162 male samples (MCS unaffected group) from 1000 genome projects were also removed. The filter reduced the total number of mutations from 1774 ⁇ 240 variations per sample to 31 ⁇ 5 variations per sample and facilitated the identification of potential disease-causing mutations.
  • ZC4H2 c.484T> A mutations consisting of allele specific amplification (ASO) and normal control (ZNF711) screening were performed using the primers in Table 1 below.
  • Zebrafish were maintained under the same reference conditions as known literature. Wild type zebrafish were purchased from an aquarium (Seoul Aquarium, Daejeon), and the food was bred by hatching commercial brine shrimp. The zebrafish were turned on at a temperature of 28.5 ° C. from 9 am to 10 pm and were bred under other time-out conditions. The fertilized eggs obtained in the zebrafish were washed with egg water (egg water, sea salts, 280 g) and generated in a petri dish. Then, the developmental process was observed through an anatomical microscope, and embryos were selected according to morphological changes over time and fixed with 4% paraformaldehyde / PBS. All experiments related to zebrafish were conducted under the approval of the Institutional Animal Care and Use Committees of Chungnam National University.
  • the zebrafish ZC4H2 gene was isolated from the 24 hpf zebrafish cDNA library, first cloned into the pGEM-T Easy Vector System (Promega, A1360) and sub-cloned using EcoRI as the pCS2 + expression vector It was. Primers used for PCR are shown in Table 2:
  • RNA probes of ZC4H2 were synthesized according to the manufacturer's protocol using DIG and Fluorescein RNA Labeling Mix, Roche catalog number 11277073910, 11685619910. .
  • appropriate timely fertilized eggs were added to 4% paraformaldehyde / PBT and fixed at 4 ° C. for at least 12 hours. More than 20 hours after fertilization, the fertilized egg was removed so that the tail was not bent after removing the chorion with the tweezers, and the fertilized egg was removed before the fertilization.
  • PBT containing 10 ⁇ g / ml proteinase K was treated in the embryo, and then washed 3 to 4 times at 5 minute intervals using PBT, and 4% paraformaldehyde. Fixed at room temperature for at least 30 minutes with / PBT. Carefully washed five times at 5 minute intervals with PBT to ensure that embryos were intact, then 300 ⁇ l HYB (50% formamide, 5X SSC, 0.1% Tween-20) was added and left at 68 ° C. for 15 minutes.
  • HYB 50% formamide, 5X SSC, 5 mg / mL toulala RNA, 50 ⁇ g / mL heparin, citric acid, pH 6, 0.1% Tween-20
  • HYB 50% formamide, 5X SSC, 5 mg / mL toulala RNA, 50 ⁇ g / mL heparin, citric acid, pH 6, 0.1% Tween-20
  • probes were added at about 30 to 100 ng for hybridization at 68 ° C. for 12 hours. Probes were removed at 68 ° C. and 100%, 75%, 50% and 25% of HYB * / 0.2X SSCT was washed sequentially every 15 minutes.
  • anti-DIG-AP Fab (150 u / 200 ⁇ l; Roche, Germany) diluted 1/4000 times in 5% horse serum / PBT was added, and at room temperature, 4 ⁇ l. The reaction was carried out at 12 hours or 4 hours at 4 ° C. After washing with PBT for 6 minutes for 10 minutes, 6 times for 20 minutes and 8 times for 30 minutes, staining buffer (0.1 M Tris-Cl pH 9.5, 0.1 M NaCl, 50 mM MgCl 2, 0.1% Tween-20) 3 washes for 5 minutes.
  • staining buffer 0.1 M Tris-Cl pH 9.5, 0.1 M NaCl, 50 mM MgCl 2, 0.1% Tween-20
  • ZC4H2 transcription was found mainly near the developing CNS but not from the medial ventricular zone where differentiation progenitors and mature neurons or / and glia are expected to be expressed (FIG. 2).
  • the transcription activator-like effector nuclease (TALEN) method was used to prepare zebrafish knocked out of the ZC4H2 gene.
  • TALEN vectors targeting the second exon of ZC4H2 were designed and constructed through ToolCen (FIG. 3).
  • TALEN vectors were linearized by PvuII and purified by ethanol precipitation.
  • Left and right TALENs encoding mRNAs were synthesized using the mMESSAGE mMACHINE T7 transcription kit (Ambion, AM1344) and purified by phenol / chloroform precipitation.
  • TALEN mRNAs were microinjected into one fertilized embryonic cell. Location-specific TALEN function was then confirmed by target-specific PCR and T7 endonuclease 1 experiments through the isolation of gDNA.
  • gDNA was isolated from single larvae or adult fin-clipped tissues and gDNA isolation buffer (10 mM Tris, 50 mM EDTA, 200 mM NaCl, 0.5% SDS and 7 0.5 mg / ml protease K). It was dissolved for 12 hours at 55 °C. gDNA was purified using phenol / chloroform method. Specifically, PCR analysis was performed with gDNA as a template with a final reaction volume of 20 ⁇ l. The primer was carried out with the primers of Table 3 below, repeated at 95 ° C. for 5 minutes once as an initial heat denaturation process, 95 ° C. 30 seconds for the denature process, 55 ° C. 30 seconds for the annealing process, and 72 ° C.
  • PCR was performed by repeating 30 seconds 30 times and repeating the polymerization process once at 72 ° C. for 7 minutes. 10 ⁇ l of the PCR reaction was electrophoresed using 1 ⁇ TAE buffer and 3% agarose gel.
  • zebrafish 5 dpf wild type and ZC4H2 gene knockout larvae were placed in slide glass in embryo medium. Zebrafish larvae were observed using stereoscopic microscopes (LEICA, MZ16), cameras (LEICA DC300FX) and microscope imaging software (LEICA, IM50). Free swim recordings and monitor displays were recorded using Camtasia Studio software (TechSmith, Vesion 7.0.0). 5 dpf zebrafish was transferred to slide glass coated with 3% methylcellulose for eye, pectoral and jaw movement observation.
  • the antisense digoxigenin-labeled RNA probes of zc4h2, gad1, glyt2a, vglut2.1, gata2, gata3, isl1, scn1Lab, vsx2, vsx1, dbx2 and nkx6.1 are selected from DIG and It was synthesized according to the manufacturer's protocol using Fluorescein RNA Labeling Mix, Roche catalog number 11277073910, 11685619910, and the whole-mount in situ hybridization of Example 4-2. The experiment was carried out in the same manner as).
  • ZC4H2 Gene Knockout When ZC4H2 gene was restored in zebrafish, the expression changes of neuron-related genes were checked to determine whether the neuronal expression and abnormal behavior induced by the mutation were restored.
  • zebrafish ZC4H2, human normal, L66H, R213W, and synthetic capped mRNAs of R18K ZC4H2 were transcribed using plasmid DNA linearized into the template via the mMESSAGE mMACHINE SP6 transcription kit (Ambion, AM1340). mRNAs were dissolved in 0.2 M KCl containing 0.2% phenol red as a tracer dye and microinjected into 1-2 cell stage embryos using PV820 Pneumatic PicoPump (WPI).
  • WPI Pneumatic PicoPump
  • the zebrafish was prepared according to the zebrafish breeding and management method of ⁇ Example 3>, a pair of ZC4H2 heterozygous knockout zebrafish male and female were put in a dedicated mating cage the afternoon of the day before the experiment, and then in a dark room. Stored. The following morning, the embryos were collected by in vitro fertilization of a pair of zebrafish male and female with light under fluorescent light. Collected fertilized eggs were transferred to Petri dishes and generated in an incubator at 28.5 ° C. The developmental process was observed through a dissecting microscope, and ZC4H2 homozygous knockout zebrafish showing abnormal movements were selected from day 4 after fertilization.
  • ZC4H2 knockout zebrafish can be used as an animal model for diseases related to dyskinesia such as epilepsy, convulsions, seizures, Parkinson's syndrome and pediatric epilepsy, and established mass screening technology for related therapeutic substances. It was.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un modèle animal transgénique ayant un gène ZC4H2 inactivé, et son utilisation. Après préparation d'un poisson zèbre ayant un gène ZC4H2 inactivé, il a été observé que le poisson zèbre ayant un gène ZC4H2 inactivé présente des symptômes de trouble de mouvement, et l'expression d'interneurones V2a, de neurones GABAergiques et de neurones inhibiteurs de V2b est réduite. Lorsque le gène ZC4H2 dans le poisson zèbre ayant un gène ZC4H2 inactivé a été rétabli, il a été confirmé que l'expression de neurones GABAergiques a été rétablie et, par conséquent, le poisson zèbre ayant un gène ZC4H2 inactivé de la présente invention peut être utilisé de manière utile dans un procédé de criblage de médicaments associés à des troubles de mouvement, y compris l'épilepsie.
PCT/KR2016/003348 2015-06-04 2016-03-31 Modèle animal transgénique ayant gène zc4h2 inactivé, et son utilisation WO2016195224A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0079135 2015-06-04
KR1020150079135A KR101750893B1 (ko) 2015-06-04 2015-06-04 Zc4h2 유전자를 녹아웃시킨 형질전환 동물모델 및 이의 용도

Publications (1)

Publication Number Publication Date
WO2016195224A1 true WO2016195224A1 (fr) 2016-12-08

Family

ID=57440977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003348 WO2016195224A1 (fr) 2015-06-04 2016-03-31 Modèle animal transgénique ayant gène zc4h2 inactivé, et son utilisation

Country Status (2)

Country Link
KR (1) KR101750893B1 (fr)
WO (1) WO2016195224A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102194833B1 (ko) * 2017-07-04 2020-12-23 고려대학교 산학협력단 우울증 또는 뇌전증 동물 모델과 그 제조방법 및 이를 이용한 우울증 또는 뇌전증 치료용 후보약물의 스크리닝 방법
WO2019009586A1 (fr) * 2017-07-04 2019-01-10 고려대학교 산학협력단 Modèle d'animal dépressif ou épileptique, procédé d'établissement s'y rapportant et procédé destiné à cribler un médicament candidat destiné au traitement d'un trouble dépressif ou d'une épilepsie utilisant ledit modèle
KR102188534B1 (ko) 2017-08-31 2020-12-08 고려대학교 산학협력단 조현병 동물모델 및 이의 제조방법
KR102122500B1 (ko) * 2018-03-07 2020-06-15 한국생명공학연구원 Dyrk1a 유전자를 녹아웃시킨 형질전환 동물모델, 및 이를 이용한 신경 장애 관련 질환 약물 스크리닝 방법
KR102109852B1 (ko) * 2018-04-05 2020-05-13 재단법인 대구경북과학기술원 뇌전증 동물 모델, 그의 제조방법 및 용도
KR102133179B1 (ko) * 2018-06-26 2020-07-13 연세대학교 산학협력단 Irx1 유전자-녹아웃 형질전환 제브라피쉬 모델 및 이의 용도
KR102328773B1 (ko) * 2019-04-23 2021-11-19 고려대학교 산학협력단 Fam19a5l 유전자를 녹아웃 시킨 제브라피쉬 동물모델 및 이의 제조방법
CN111944835B (zh) * 2019-05-14 2022-03-29 南通大学 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用
KR102271414B1 (ko) * 2019-08-28 2021-07-01 충남대학교산학협력단 Fam50a 유전자를 녹아웃시킨 동물모델 및 이의 용도
CN111304251A (zh) * 2020-03-12 2020-06-19 南通大学 一种斑马鱼难治性癫痫模型的构建方法及应用
KR102612878B1 (ko) * 2021-01-22 2023-12-13 충남대학교산학협력단 eif2b3 유전자를 녹아웃시킨 동물모델 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020016986A (ko) * 2000-08-28 2002-03-07 허태린 신경특이적 유전자 발현을 조절하는제브라피쉬의ＨｕＣ프로모터 유전자, 이를 이용한 형광성신경을 갖는 형질전환 동물 및 그의 제조방법, 그리고이를 이용한 신경변이체 동물의 선별방법
US20020187921A1 (en) * 2001-04-04 2002-12-12 Rubeinstein Amy K. Transgenic zebrafish models for neurodegenerative disease
US20080201786A1 (en) * 2005-01-27 2008-08-21 Zygogen, Llp Transgenic Zebrafish Models of Alzheimer's Disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020016986A (ko) * 2000-08-28 2002-03-07 허태린 신경특이적 유전자 발현을 조절하는제브라피쉬의ＨｕＣ프로모터 유전자, 이를 이용한 형광성신경을 갖는 형질전환 동물 및 그의 제조방법, 그리고이를 이용한 신경변이체 동물의 선별방법
US20020187921A1 (en) * 2001-04-04 2002-12-12 Rubeinstein Amy K. Transgenic zebrafish models for neurodegenerative disease
US20080201786A1 (en) * 2005-01-27 2008-08-21 Zygogen, Llp Transgenic Zebrafish Models of Alzheimer's Disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 26 January 2014 (2014-01-26), "Zinc Finger C4H2 Domain-containing Protein [Danio Rerio", Database accession no. NP 955936.1 *
HIRATA, H. ET AL.: "ZC4H2 Mutations are associated with Arthrogryposis Multiplex Congenita and Intellectual Disability through Impairment of Central and Peripheral Synaptic Plasticity", AM. J. HUM. GENET., vol. 92, no. 5, 2 May 2013 (2013-05-02), pages 681 - 695, XP055334945 *

Also Published As

Publication number Publication date
KR20160143913A (ko) 2016-12-15
KR101750893B1 (ko) 2017-07-12

Similar Documents

Publication Publication Date Title
WO2016195224A1 (fr) Modèle animal transgénique ayant gène zc4h2 inactivé, et son utilisation
Saxton et al. Kinesin heavy chain is essential for viability and neuromuscular functions in Drosophila, but mutants show no defects in mitosis
Baoprasertkul et al. Divergent Toll-like receptors in catfish (Ictalurus punctatus): TLR5S, TLR20, TLR21
AU2005200741A1 (en) Novel Odorant Receptors in Drosophila
Nie et al. CRISPR/Cas9 mediated knockout of Amyellow-y gene results in melanization defect of the cuticle in adult Apis mellifera
Wang et al. Production of YY males through self-fertilization of an occasional hermaphrodite in Lanzhou catfish (Silurus lanzhouensis)
Zhang et al. Sleep and circadian abnormalities precede cognitive deficits in R521C FUS knockin rats
Toyota et al. Comparative developmental staging of female and male water fleas Daphnia pulex and Daphnia magna during embryogenesis
CN108642129A (zh) 冲动控制紊乱生物检测标记物和Impulsins的医药用途
Posner et al. Impact of α-crystallin protein loss on zebrafish lens development
Hanly et al. A large deletion at the cortex locus eliminates butterfly wing patterning
Li et al. Tilapia, a good model for studying reproductive endocrinology
Berthod et al. In vivo and in vitro models to study amyotrophic lateral sclerosis
Krivoruchko et al. New candidate genes of high productivity in North-Caucasian sheep using genome-wide association study (GWAS)
Eberlein Stage specific embryonic defects following heat shock in Drosophila
Li et al. Ap4s1 truncation leads to axonal defects in a zebrafish model of spastic paraplegia 52
Chen et al. Multiple abnormalities due to a nonsense mutation in the Alx4 gene
KR102351161B1 (ko) Rnf220 유전자를 녹아웃시킨 형질전환 동물모델 및 이의 용도
WO2020218731A1 (fr) Modèle animal transgénique à invalidation génétique fam19a5l et son procédé de production
KR102612878B1 (ko) eif2b3 유전자를 녹아웃시킨 동물모델 및 이의 용도
KR102271414B1 (ko) Fam50a 유전자를 녹아웃시킨 동물모델 및 이의 용도
Dubin et al. Sexual antagonism and sex determination in three syngnathid species alongside a male pregnancy gradient
WO2017104967A1 (fr) Modèle de poisson zèbre dans lequel le gène mutant dgat2 a été introduit, et utlisation de ce modèle
CN114990160B (zh) 一种Navβ2-ICD低表达转基因鼠模型的构建方法及其应用
Qin Genetic Analysis of Transcription Factors Involved in Zebrafish Sex Differentiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16803579

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16803579

Country of ref document: EP

Kind code of ref document: A1